In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 12 selected

Guidance programme

Showing 101 to 150 of 408

TitleTypeExpected publication date
Digital technologies for multidisciplinary weight managementHealth technology evaluationTBC
Domestic AbuseNICE guideline
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]Technology appraisal guidanceTBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Technology appraisal guidanceTBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]Technology appraisal guidance
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]Technology appraisal guidanceTBC
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]Highly specialised technologyTBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Technology appraisal guidanceTBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID6235]Technology appraisal guidance
Dupilumab for treating bullous pemphigoid [ID6479]Technology appraisal guidanceTBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]Technology appraisal guidanceTBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]Technology appraisal guidance
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]Technology appraisal guidanceTBC
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer [ID6168]Technology appraisal guidance
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317Technology appraisal guidanceTBC
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]Technology appraisal guidanceTBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]Technology appraisal guidanceTBC
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)NICE guideline
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]Technology appraisal guidance
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Technology appraisal guidanceTBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]Technology appraisal guidanceTBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]Technology appraisal guidanceTBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]Technology appraisal guidanceTBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaInterventional procedures guidanceTBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]Technology appraisal guidanceTBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]Technology appraisal guidanceTBC
Ensitrelvir for treating COVID 19 [ID6231]Technology appraisal guidanceTBC
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]Technology appraisal guidanceTBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]Technology appraisal guidance
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]Technology appraisal guidance
Epilepsies in children, young people and adultsNICE guidelineTBC
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]Technology appraisal guidanceTBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Technology appraisal guidanceTBC
Ex-situ machine perfusion devices for deceased donor liver transplantsHealth technology evaluation
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology testsDiagnostics guidanceTBC
Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac deathInterventional procedures guidanceTBC
Familial Breast Cancer: initial assessment and genetic testing (update)NICE guideline
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]Technology appraisal guidanceTBC
Fertility problems: assessment and treatment - update 1 and 2NICE guideline
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Technology appraisal guidanceTBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Technology appraisal guidanceTBC
Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]Technology appraisal guidanceTBC
Filgotinib for treating axial spondyloarthritis [ID6594]Technology appraisal guidanceTBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]Technology appraisal guidance
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]Technology appraisal guidanceTBC
Gantenerumab for treating early Alzheimer's disease [ID6142]Technology appraisal guidanceTBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All